

TOWNSEND and TOWNSEND and CREW LLP

By *Therese L. Penber*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Miles W. Carroll, et al.

Application No.: 10/774,176

Filed: February 6, 2004

For: POLYPEPTIDE

Customer No. 20350

Confirmation No.: 7186

Examiner: Marianne NMN Dibrino

Art Unit: 1644

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The additional references cited on attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of references AS-BL in compliance with the requirements of 37 CFR §1.98(a)(2) are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or
Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please
deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kawai Lau
Reg. No. 44,461

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 858-350-6100
Fax: 415-576-0300
KL:tsp

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/774,176
		Filing Date	February 6, 2004
		First Named Inventor	Carroll, Miles W.
		Art Unit	1644
Examiner Name	Marianne NMN Dibrino		
Attorney Docket Number	021911-000510US		
Sheet	1	of	3

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	US-4,558,055		12/10/1985	Johnson	
	AB	US-5,969,053		02/09/1999	Stern, et al	
	AC	US-				
	AD	US-				
	AE	US-				
	AF	US-				
	AG	US-				
	AH	US-				
	AI	US-				
	AJ	US-				
	AK	US-				
	AL	US-				
	AM	US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†*
		Country Code ²	Number ³	Kind Code ⁴ (if known)				
	AN							<input type="checkbox"/>
	AO							<input type="checkbox"/>
	AP							<input type="checkbox"/>
	AQ							<input type="checkbox"/>
	AR							<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

61000823 v1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **2** of **3****Complete if Known**

Application Number	10/774,176
Filing Date	February 6, 2004
First Named Inventor	Carroll, Miles W.
Art Unit	1644
Examiner Name	Marianne NMN Dibrino
Attorney Docket Number	021911-000510US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AS	COULIE P. "Human Tumor Antigens Recognized by Cytolytic T Lymphocytes", Chapter 5, pages 95-125, <i>Tumor Immunology</i> , Eds. Dagleish & Browning, Cambridge University Press 1996	<input type="checkbox"/>
	AT	ROSENKRANTZ, K., et al. "Generation and regulation of autotoxicity in mixed lymphocyte cultures: Evidence for active suppression of autotoxic cells", <i>PNAS</i> (1985) 82:4508-4512	<input type="checkbox"/>
	AU	STAVELY-O'CARROLL, et al. "Induction of antigen-specific T cell energy: An early event in the course of tumor progression", <i>PNAS</i> (1998) 95:1178-1183	<input type="checkbox"/>
	AV	MANSON, L., et al. "Short Analytical Review - Anti-tumor Immune Responses of the Tumor Bearing Host: The Case for Antibody-Mediated Immunologic Enhancement", <i>Clinical Immunology & Immunopathology</i> (1994) 72(1):1-8	<input type="checkbox"/>
	AW	GANSS, R., et al. "Tumor Microenvironment Can Restrict the Effectiveness of Activated Antitumor Lymphocytes", <i>Cancer Research</i> (1998) 58:4673-4681	<input type="checkbox"/>
	AX	BERD, D. "Cancer Vaccines: Reborn or Just Recycled?", <i>Seminars in Oncology</i> (1998) 25(6):805-810	<input type="checkbox"/>
	AY	HERSEY, P., et al. "Impediments to Successful Immunotherapy", <i>Pharmacol. Ther.</i> (1999) 81(2):111-119	<input type="checkbox"/>
	AZ	TAKAHASHI, K., et al. "Escape Mechanisms of Melanoma From Immune System By Soluble Melanoma Antigen", <i>The Journal of Immunology</i> (1988) 140(9):3244-3248	<input type="checkbox"/>
	BA	JANEWAY & TRAVERS, <i>Immunobiology: The Immune System in Health and Disease</i> , Third edition, Current Biology Ltd./Garland Publishing Inc. (1997)	<input type="checkbox"/>
	BB	AMATO, R., et al. "Phase II Trial to Assess the Activity of MVA 5T4 (Troxax®) alone versus MVA 5T4 plus Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in Patients (pts) with Progressive Hormone Refractory Prostate Cancer (HRPC)", Abstract, 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", 7-10 November 2006, Prague, Czech Republic	<input type="checkbox"/>
	BC	AMATO, R., et al. "Activity of MVA 5T4 alone or in Combination with either Interleukin-2 (IL-2), Interferon- α (IFN), or Sunitinib in Patients (Pts) with Metastatic Renal Cell Cancer (MRCC)", Abstract, 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", 7-10 November 2006, Prague, Czech Republic	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449BPTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **3** of **3****Complete if Known**

Application Number	10/774,176
Filing Date	February 6, 2004
First Named Inventor	Carroll, Miles W.
Art Unit	1644
Examiner Name	Marianne NMN Dibrino
Attorney Docket Number	021911-000510US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BD	SYKULEV, Y., et al. "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response", <i>Immunity</i> (1996) 4:565-571	<input type="checkbox"/>
	BE	STERN, Peter, et al. "Characterization of the Human Trophoblast-Leukocyte Antigenic Molecules Defined by a Monoclonal Antibody", <i>The Journal of Immunology</i> (1986) 137(5):1604-1609	<input type="checkbox"/>
	BF	JOHNSON, P.M., et al. "Human Trophoblast-Specific Surface Antigens Identified Using Monoclonal Antibodies", <i>American Journal of Reproductive Immunology</i> (1981) 1:246-254	<input type="checkbox"/>
	BG	RETTIG, Wolfgang J., et al. "Cell Surface Antigens of Human Trophoblast and Choriocarcinoma Defined by Monoclonal Antibodies", <i>Int. J. Cancer</i> (1985) 35:469-475	<input type="checkbox"/>
	BH	HOLE, M., et al. "Trophoblast-Specific Glycoprotein Defined by Monoclonal Antibody 5T4", <i>British Society for Immunology & British Transplantation Society 1986 Joint Annual Meeting</i> , November 12-14, 1986, abstract 66.	<input type="checkbox"/>
	BI	STERN, P.L. et al. "Molecular Characterisation of Human Terato-Carcinoma-Trophoblast Cell Surface Antigens", <i>J. Repro. Immun., Supp.</i> 6 (June 1986)	<input type="checkbox"/>
	BJ	ANDERSON, Deborah J., et al. "Monoclonal antibodies to human trophoblast and sperm antigens: Report of two WHO sponsored workshops, June 30, 1986 - Toronto, Canada <i>J. Repro. Immun.</i> (1987) 10:231-257	<input type="checkbox"/>
	BK	CHO, S.-W., et al. "Characterization of three monoclonal antibodies to membrane co-factor protein (MCP) of the complement system and quantification of MCP by radioassay", <i>Clin. Exp. Immunol.</i> (1991) 83:257-261	<input type="checkbox"/>
	BL	PURCELL, D.F.J., et al. "The human cell-surface glycoproteins HuLy-m5, membrane co-factor protein (MCP) of the complement system, and trophoblast leucocyte-common (TLX) antigen, are CD48", <i>Immunology</i> (1990) 70:155-161	<input type="checkbox"/>
	BM		<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.